Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Case report

Synchronous cancers of gallbladder carcinoma and combined hepatocellular cholangiocarcinoma: an unusual case and literature review

Authors: Zhan-Guo Zhang, Yan Chen, Ran Ji, Ya-Jie Zhao, Jian Wang, Lily Robinson, Xiao-Ping Chen, Lei Zhang

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Synchronous primary cancers in gallbladder and liver are rarely reported. Here we report an unusual case of synchronous cancers of gallbladder carcinoma and combined hepatocellular cholangiocarcinoma.

Case presentation

Several lesions in the gallbladder and in adjacent parenchyma of liver were discovered in a 65-years-old woman by imaging examination. Surgical resection was performed following a diagnosis of primary gallbladder carcinoma with local hepatic metastasis. Histological examination confirmed the diagnosis of primary gallbladder carcinoma, and the lesions in the liver consisted of hepatocellular carcinoma simultaneously with cholangiocarcinoma. Adjuvant chemoradiation therapy was not performed due to the patient’s refusal of the treatment. Unfortunately, the patient died of widespread metastasis 8 months after the operation.

Conclusions

The disease needed to be differentially diagnosed from gallbladder carcinoma with hepatic metastasis. Aggressive surgical approach should be based on a balance between the risk of surgery (morbidity and mortality) and the outcome.
Literature
1.
go back to reference Zeng QA, Qiu J, Zou R, et al. Clinical features and outcome of multiple primary malignancies involving hepatocellular carcinoma: a long-term follow-up study. BMC Cancer. 2012;12:148.CrossRef Zeng QA, Qiu J, Zou R, et al. Clinical features and outcome of multiple primary malignancies involving hepatocellular carcinoma: a long-term follow-up study. BMC Cancer. 2012;12:148.CrossRef
2.
go back to reference Demandante CG, Troyer DA, Miles TP. Multiple primary malignant neoplasms: case report and a comprehensive review of the literature. Am J Clin Oncol. 2003;26:79–83.CrossRef Demandante CG, Troyer DA, Miles TP. Multiple primary malignant neoplasms: case report and a comprehensive review of the literature. Am J Clin Oncol. 2003;26:79–83.CrossRef
3.
go back to reference Warren S, Gates O. Multiple primary maligant tumors: a survey of the literature and a statistical study. Am J Cancer. 1932;16:1358–414. Warren S, Gates O. Multiple primary maligant tumors: a survey of the literature and a statistical study. Am J Cancer. 1932;16:1358–414.
4.
go back to reference Lee JH, Bae JS, Ryu KW, Lee JS, Park SR, Kim CG, Kook MC, Choi IJ, Kim YW, Park JG, Bae JM. Gastric cancer patients at high-risk of having synchronous cancer. World J Gastroenterol. 2006;12:2588–92.CrossRef Lee JH, Bae JS, Ryu KW, Lee JS, Park SR, Kim CG, Kook MC, Choi IJ, Kim YW, Park JG, Bae JM. Gastric cancer patients at high-risk of having synchronous cancer. World J Gastroenterol. 2006;12:2588–92.CrossRef
5.
go back to reference Imada J, Hoshino H, Nishimura D, et al. Case report: multiple cancers: hepatocellular carcinoma and adenocarcinomas of the common bile duct and the gall-bladder in a woman with primary biliary cirrhosis. J Gastroenterol Hepatol. 1996;11:546–50.CrossRef Imada J, Hoshino H, Nishimura D, et al. Case report: multiple cancers: hepatocellular carcinoma and adenocarcinomas of the common bile duct and the gall-bladder in a woman with primary biliary cirrhosis. J Gastroenterol Hepatol. 1996;11:546–50.CrossRef
6.
go back to reference Taniai N, Onda M, Tajiri T, et al. Synchronous carcinoma of the gallbladder in a patient with intrahepatic bile duct carcinoma. Hepatogastroenterology. 2000;47:121–4.PubMed Taniai N, Onda M, Tajiri T, et al. Synchronous carcinoma of the gallbladder in a patient with intrahepatic bile duct carcinoma. Hepatogastroenterology. 2000;47:121–4.PubMed
7.
go back to reference La Greca G, Barbagallo F, Rodolico M, et al. Hepatocarcinoma, gallstone disease and gallbladder carcinoma: a case report of a rare incidental association. Chir Ital. 2004;56:571–4.PubMed La Greca G, Barbagallo F, Rodolico M, et al. Hepatocarcinoma, gallstone disease and gallbladder carcinoma: a case report of a rare incidental association. Chir Ital. 2004;56:571–4.PubMed
8.
go back to reference Kim JW, Han JW, Jung SY, et al. Synchronous double primary malignant tumor of the gallbladder and liver: a case report. World J Surg Oncol. 2011;9:84.CrossRef Kim JW, Han JW, Jung SY, et al. Synchronous double primary malignant tumor of the gallbladder and liver: a case report. World J Surg Oncol. 2011;9:84.CrossRef
9.
go back to reference Unver M, Ozturk S, Bozbiyik O, et al. Incidental early gallbladder carcinoma with hepatocellular carcinoma: a rare synchronous double primary malignant tumor. J Med Cases. 2014;5:561–3.CrossRef Unver M, Ozturk S, Bozbiyik O, et al. Incidental early gallbladder carcinoma with hepatocellular carcinoma: a rare synchronous double primary malignant tumor. J Med Cases. 2014;5:561–3.CrossRef
10.
go back to reference Lu J, Xiong XZ, Cheng NS. Hepatobiliary and pancreatic: coexisting cancers: hepatic neuroendocrine carcinomas with gallbladder adenocarcinoma. J Gastroenterol Hepatol. 2014;29:1343.CrossRef Lu J, Xiong XZ, Cheng NS. Hepatobiliary and pancreatic: coexisting cancers: hepatic neuroendocrine carcinomas with gallbladder adenocarcinoma. J Gastroenterol Hepatol. 2014;29:1343.CrossRef
11.
go back to reference Jakab C, Rusvai M, Szabó Z, et al. Claudin-7-positive synchronous spontaneous intrahepatic cholangiocarcinoma, adenocarcinoma and adenomasof the gallbladder in a bearded dragon (Pogona vittticeps). Acta Vet Hung. 2011;59:99–112.CrossRef Jakab C, Rusvai M, Szabó Z, et al. Claudin-7-positive synchronous spontaneous intrahepatic cholangiocarcinoma, adenocarcinoma and adenomasof the gallbladder in a bearded dragon (Pogona vittticeps). Acta Vet Hung. 2011;59:99–112.CrossRef
12.
go back to reference Kim KH, Lee SG, Park EH, et al. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol. 2009;16:623–9.CrossRef Kim KH, Lee SG, Park EH, et al. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol. 2009;16:623–9.CrossRef
13.
go back to reference Groot Koerkamp B, Fong Y. Outcomes in biliary malignancy. J Surg Oncol. 2014;110:585–91.CrossRef Groot Koerkamp B, Fong Y. Outcomes in biliary malignancy. J Surg Oncol. 2014;110:585–91.CrossRef
16.
go back to reference Dwivedi AN, Jain S, Dixit R. Gall bladder carcinoma: aggressive malignancy with protean loco-regional and distant spread. World J Clin Cases. 2015;3:231–44.CrossRef Dwivedi AN, Jain S, Dixit R. Gall bladder carcinoma: aggressive malignancy with protean loco-regional and distant spread. World J Clin Cases. 2015;3:231–44.CrossRef
17.
go back to reference Dutta U. Gallbladder cancer: can newer insights improve the outcome? J Gastroenterol Hepatol. 2012;27:642–53.CrossRef Dutta U. Gallbladder cancer: can newer insights improve the outcome? J Gastroenterol Hepatol. 2012;27:642–53.CrossRef
18.
go back to reference Bret PM, Labadie M, Bretagnolle M, et al. Hepatocellular carcinoma: diagnosis by percutaneous fine needle biopsy. Gastrointest Radiol. 1988;13:253–5.CrossRef Bret PM, Labadie M, Bretagnolle M, et al. Hepatocellular carcinoma: diagnosis by percutaneous fine needle biopsy. Gastrointest Radiol. 1988;13:253–5.CrossRef
19.
go back to reference Kim SH, Lim HK, Lee WJ, et al. Needle-tract implantation in hepatocellular carcinoma: frequency and CT findings after biopsy with a 19.5-gauge automated biopsy gun. Abdom Imaging. 2000;25:246–50.CrossRef Kim SH, Lim HK, Lee WJ, et al. Needle-tract implantation in hepatocellular carcinoma: frequency and CT findings after biopsy with a 19.5-gauge automated biopsy gun. Abdom Imaging. 2000;25:246–50.CrossRef
20.
go back to reference Kim C, Chon H, Kang B, Jung JP, Kim JW. Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. BMC Cancer. 2013;13:394.CrossRef Kim C, Chon H, Kang B, Jung JP, Kim JW. Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. BMC Cancer. 2013;13:394.CrossRef
21.
go back to reference Park SL, Caberto CP, Lin Y, et al. Association of cancer susceptibility variants with risk of multiple primary cancers: the population architecture using genomics and epidemiology study. Cancer Epidemiol Biomark Prev. 2014;23:2568–78.CrossRef Park SL, Caberto CP, Lin Y, et al. Association of cancer susceptibility variants with risk of multiple primary cancers: the population architecture using genomics and epidemiology study. Cancer Epidemiol Biomark Prev. 2014;23:2568–78.CrossRef
22.
go back to reference Stinton LM, Eldon A, Shaffer EA. Epidemiology of gallbladder disease: Cholelithiasis and Cancer. Gut Liver. 2012;6:172–87.CrossRef Stinton LM, Eldon A, Shaffer EA. Epidemiology of gallbladder disease: Cholelithiasis and Cancer. Gut Liver. 2012;6:172–87.CrossRef
23.
go back to reference Wachtel MS, Zhang Y, Xu T, et al. Combined hepatocellular cholangiocarcinomas; analysis of a large database. Clin Med Pathol. 2008;1:43–7.CrossRef Wachtel MS, Zhang Y, Xu T, et al. Combined hepatocellular cholangiocarcinomas; analysis of a large database. Clin Med Pathol. 2008;1:43–7.CrossRef
24.
go back to reference O'Connor K, Walsh JC, Schaeffer DF. Combined hepatocellular- cholangiocarcinoma (cHCC-CC): a distinct entity. Ann Hematol. 2014;13:317–22. O'Connor K, Walsh JC, Schaeffer DF. Combined hepatocellular- cholangiocarcinoma (cHCC-CC): a distinct entity. Ann Hematol. 2014;13:317–22.
25.
go back to reference Komuta M, Spee B, Vander Borght S, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008;47:1544–56.CrossRef Komuta M, Spee B, Vander Borght S, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008;47:1544–56.CrossRef
26.
go back to reference Fujii H, Zhu XG, Matsumoto T, et al. Genetic classification of combined hepatocellular-cholangiocarcinoma. Hum Pathol. 2000;31:1011–7.CrossRef Fujii H, Zhu XG, Matsumoto T, et al. Genetic classification of combined hepatocellular-cholangiocarcinoma. Hum Pathol. 2000;31:1011–7.CrossRef
27.
go back to reference Zhang F, Chen XP, Zhang W, et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology. 2008;52:224–32.CrossRef Zhang F, Chen XP, Zhang W, et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology. 2008;52:224–32.CrossRef
28.
go back to reference Berasain C, Castillo J, Perugorria MJ, et al. Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci. 2009;1155:206–21.CrossRef Berasain C, Castillo J, Perugorria MJ, et al. Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci. 2009;1155:206–21.CrossRef
29.
go back to reference Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436–44.CrossRef Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436–44.CrossRef
Metadata
Title
Synchronous cancers of gallbladder carcinoma and combined hepatocellular cholangiocarcinoma: an unusual case and literature review
Authors
Zhan-Guo Zhang
Yan Chen
Ran Ji
Ya-Jie Zhao
Jian Wang
Lily Robinson
Xiao-Ping Chen
Lei Zhang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4969-2

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine